rawfin.tv
Cellectar Biosciences Enrolls First Patient in CLR 125 Trial
MarketsstocksAI Generated

Cellectar Biosciences Enrolls First Patient in CLR 125 Trial

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Cellectar Biosciences has enrolled the first patient in its Phase 1b clinical trial for CLR 125, targeting refractory triple-negative breast cancer. This milestone marks progress for the Auger-emitting radiopharmaceutical.

CLRBClinical TrialsBiotechnologyCancer TreatmentPharmaceuticals

Related Articles

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks
Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

stocks
Ambarella Gains as Nvidia Emerges as Potential Third Bidder

Ambarella Gains as Nvidia Emerges as Potential Third Bidder

stocks
SpaceX and Tesla Boards Review Potential $3.5 Trillion Merger

SpaceX and Tesla Boards Review Potential $3.5 Trillion Merger

stocks